CoChat

Empagliflozin compared with glimepiride in metformin‐treated patients with type 2 diabetes: 208‐week data from a masked randomized controlled trial

Ridderstråle, Martin, Rosenstock, Julio, Andersen, Knut R., Woerle, Hans J., Salsali, Afshin, on behalf of the EMPA‐REG H2H‐SU trial investigators · 2018 · Diabetes, Obesity and Metabolism
Cited by 51

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Aim: To report results at week 208, including a 104‐week masked extension, of the EMPA‐REG H2H‐SU trial in patients with type 2 diabetes with inadequate glycaemic control on metformin, in which empagliflozin 25 mg given for 104 weeks provided a sustained reduction in glycated haemoglobin (HbA1c) with a small but statistically significant benefit vs glimepiride, sustained reductions in weight and blood pressure, and low risk of hypoglycaemia. Research Design and Methods: Patients with type 2 diabetes and HbA1c 53‐86 mmol/mol (7% to 10%) were randomized to empagliflozin 25 mg or glimepiride 1 to 4 mg for 104 weeks as add‐on to metformin. Patients who completed the randomized treatment period could participate in a 104‐week extension in which they continued the double‐blind treatment allocated at randomization. Results: Of 765 and 780 patients treated with empagliflozin and glimepiride, 576 and 549 patients, respectively, entered the extension period of the study. At week 208, the adjusted mean difference in change from baseline in HbA1c with empagliflozin vs glimepiride was −1.96 mmol/mol, 95% CI −3.57, −0.35 (−0.18%, 95% CI −0.33, −0.03); P = 0.0172. Rescue therapy was given to 23% of patients on empagliflozin and 34% on glimepiride (odds ratio 0.56 [95% CI 0.45, 0.71]; P < 0.0001). Confirmed hypoglycaemic adverse events (plasma glucose ≤3.9 mmol/L and/or requiring assistance) occurred in 3% of patients on empagliflozin and 28% on glimepiride (odds ratio 0.08 [95% CI 0.05, 0.13]; P < 0.0001). Conclusions: In patients with type 2 diabetes, empagliflozin 25 mg as add‐on to metformin for 208 weeks reduced HbA1c with a significantly lower risk of hypoglycaemia and a significantly smaller proportion of patients receiving rescue therapy compared with glimepiride.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.13457

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 51

Metadata

Authors
Ridderstråle, M., Rosenstock, J., Andersen, K. R., Woerle, H. J., Salsali, A., & on behalf of the EMPA‐REG H2H‐SU trial investigators
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2018-08-07
Volume
20
Issue
12
Pages
2768-2777
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2809903778
Cited by
51
References
5
FWCI
3.92
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Empagliflozin compared with glimepiride in metformin‐treated patients with type 2 diabetes: 208‐week data from a masked randomized controlled trial. https://app.cochat.ai/papers/10.1111/dom.13457
The paper
Ridderstråle, M., Rosenstock, J., Andersen, K. R., Woerle, H. J., Salsali, A., & on behalf of the EMPA‐REG H2H‐SU trial investigators. (2018). Empagliflozin compared with glimepiride in metformin‐treated patients with type 2 diabetes: 208‐week data from a masked randomized controlled trial. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.13457

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.